COSCIENS Biopharma Announces Change to Board of Directors
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a specialty biopharmaceutical company, has announced a change to its Board of Directors. Carolyn Egbert has resigned from the Board, effective immediately. Egbert served on the Board for twelve years, including eight years as Chair. The company has decided to streamline its board structure, moving forward with six members, including five independent directors. This decision aligns more closely with industry standards for companies at COSCIENS' stage. Ronald Miller, the current Chair of the Board, expressed gratitude for Egbert's dedicated service and valuable contributions to the company, previously known as Aeterna Zentaris.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), un'azienda biopharmaceuticale specializzata, ha annunciato un cambiamento nel suo Consiglio di Amministrazione. Carolyn Egbert si è dimessa dal Consiglio, con effetto immediato. Egbert ha servito nel Consiglio per dodici anni, di cui otto come Presidente. L'azienda ha deciso di snellire la sua struttura consiliare, proseguendo con sei membri, di cui cinque sono direttori indipendenti. Questa decisione si allinea più strettamente con gli standard dell'industria per aziende nella fase di COSCIENS. Ronald Miller, l'attuale Presidente del Consiglio, ha espresso gratitudine per il servizio dedicato di Egbert e per i suoi preziosi contributi all'azienda, precedentemente conosciuta come Aeterna Zentaris.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), una compañía biofarmacéutica especializada, ha anunciado un cambio en su Junta Directiva. Carolyn Egbert ha renunciado a la Junta, con efecto inmediato. Egbert formó parte de la Junta durante doce años, incluidos ocho como Presidenta. La compañía ha decidido agilizar su estructura directiva, avanzando con seis miembros, de los cuales cinco son directores independientes. Esta decisión se alinea más estrechamente con los estándares de la industria para empresas en la etapa de COSCIENS. Ronald Miller, el actual Presidente de la Junta, expresó su agradecimiento por el servicio dedicado de Egbert y sus valiosas contribuciones a la compañía, que anteriormente se conocía como Aeterna Zentaris.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), 특수 생명공학 제약 회사가 이사회의 변화를 발표했습니다. 캐롤린 에그버트가 이사회에서 사임했습니다, 즉시 시행됩니다. 에그버트는 이사회에서 12년 동안 근무했으며, 그 중 8년은 의장으로 일했습니다. 회사는 이사회 구조를 간소화하기로 결정하였습니다, 6명의 이사로 진행하며 그 중 5명은 독립 이사입니다. 이 결정은 COSCIENS 단계의 기업에 대한 산업 표준과 더욱 밀접하게 일치합니다. 현재 이사회 의장인 로널드 밀러는 에그버트의 헌신적인 서비스와 회사에 대한 귀중한 기여에 감사의 뜻을 표했습니다. 이 회사는 이전에 Aeterna Zentaris로 알려져 있었습니다.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), une société biopharmaceutique spécialisée, a annoncé un changement au sein de son Conseil d'Administration. Carolyn Egbert a démissionné du Conseil, avec effet immédiat. Egbert a siégé au Conseil pendant douze ans, dont huit en tant que Présidente. L'entreprise a décidé de rationaliser sa structure de conseil, avançant avec six membres, dont cinq directeurs indépendants. Cette décision est plus en phase avec les normes de l'industrie pour des entreprises à l'étape de COSCIENS. Ronald Miller, l'actuel Président du Conseil, a exprimé sa gratitude pour le service dévoué d'Egbert et ses contributions précieuses à l'entreprise, auparavant connue sous le nom d'Aeterna Zentaris.
COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), ein auf biopharmazeutische Produkte spezialisiertes Unternehmen, hat eine Änderung im Vorstand bekannt gegeben. Carolyn Egbert hat mit sofortiger Wirkung aus dem Vorstand resigniert. Egbert war zwölf Jahre im Vorstand tätig, davon acht Jahre als Vorsitzende. Das Unternehmen hat entschieden, seine Vorstandsstruktur zu optimieren und künftig mit sechs Mitgliedern, einschließlich fünf unabhängigen Direktoren, fortzufahren. Diese Entscheidung steht in enger Übereinstimmung mit den Branchenstandards für Unternehmen in COSCIENS' Phase. Ronald Miller, der aktuelle Vorsitzende des Vorstands, äußerte Dankbarkeit für Egberts engagierten Dienst und wertvolle Beiträge zum Unternehmen, das zuvor als Aeterna Zentaris bekannt war.
- Board restructuring to align with industry standards
- Maintaining a majority of independent directors (5 out of 6)
- Loss of a long-serving board member with 12 years of experience
- Reduction in board size from at least 7 to 6 members
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the resignation of Carolyn Egbert from the Board of Directors, effective immediately.
“We are extremely grateful to Carolyn for her twelve years of dedicated service to the Company as a member of the Board of Directors, including serving eight years as Chair. Throughout her tenure as a board member of Aeterna Zentaris, now CONSCIENS, she provided valuable contributions and insight,” said Chair of the Board, Ronald Miller. “With Carolyn’s decision to resign from the Board and as the Company continues to evolve at various levels, we have made the strategic decision to streamline our board structure and move forward with six members, including five independent directors which we believe more closely aligns with the industry standard for a Company at our stage.”
About COSCIENS Biopharma Inc.
COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency (“AGHD”). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol "CSCI". For more information, please visit COSCIENS' website at www.cosciensbio.com.
Forward-Looking Statements
The information in this news release has been prepared as of October 1, 2024. Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.
Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in Childhood Growth Hormone Deficiency may impact the market for macimorelin (Macrilen®; Ghryvelin®) in AGHD and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market.
Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.
Issuer:
Gilles R. Gagnon
President & CEO
ggagnon@ceapro.com
+1 (780) 421-4555
Investor Contact:
Jenene Thomas
JTC Team
T (US): +1 (908) 824-0775
E: csci@jtcir.com
FAQ
Why did Carolyn Egbert resign from COSCIENS Biopharma's (CSCI) Board of Directors?
How long did Carolyn Egbert serve on COSCIENS Biopharma's (CSCI) Board of Directors?
How many members will COSCIENS Biopharma's (CSCI) Board of Directors have after this change?
Who is the current Chair of COSCIENS Biopharma's (CSCI) Board of Directors?
